GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A8974 G-Protein antagonist peptide TFA -
A8975 CTOP TFA -
A8991 TolazolineSummary: An α2-adrenergic receptor antagonist -
A8999 AZA1 -
A9025 Tecadenoson (CVT-510) -
A9037 MS21570 -
A9917 NafadotrideSummary: An antagonist of the dopamine D3 receptor -
A9921 NE 52-QQ57Summary: A selective oral G-protein-coupled receptor 4 (GPR4) antagonist -
A9922 Methoxamine hydrochlorideSummary: An α1-adrenergic receptor selective agonist -
A9931 Argipressin acetateSummary: A peptide hormone with vasoconstrictive and antidiuretic properties

